Larvol Delta - Algernon-Pharmaceuticals-Announces-Reduction-of-Key-Secondary-Marker-of-Fibrosis-in-PreClinical-NASH-Study

NP-135 - Breathtec Biomedical

cenicriviroc (TBR-652) - Allergan, Takeda

http://www.globenewswire.com/news-release/2019/04/01/1790501/0/en/Algernon-Pharmaceuticals-Announces-Reduction-of-Key-Secondary-Marker-of-Fibrosis-in-Pre-Clinical-NASH-Study.html

Apr 1, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next